Fig. 6

Wedelolactone treatment ameliorates immune-cell infiltration and reduces islet NF-κB signalling activation.(A) Schematic of the experimental approach. Tg(ins:il1b);Tg(NF-kB:GFP) embryos were treated with DMSO or wedelolactone (WED) from 1 to 3.5 dpf. At 3.5 dpf, the presence of L-plastin-positive leukocytes in the islet region was quantified. (B) Representative confocal images of Tg(ins:il1b);Tg(NF-kB:GFP) embryos treated with DMSO or 30 μM wedelolactone. Whereas the leukocytes have infiltrated the islet in DMSO controls, there is a reduction in islet-associated immune cells following wedelolactone treatment. (C) Quantification of the number of L-plastin-expressing cells in the islets of DMSO- and wedelolactone-treated larvae. One-way ANOVA with Sidak's multiple-comparison test; **P≤0.01; ns, not significant. Mean±s.d. (D) Representative confocal images of the islets of Tg(ins:il1b);Tg(NF-kB:GFP) embryos treated with DMSO or wedelolactone from 1 to 4 dpf. Wedelolactone-treated larvae show a visible reduction in NF-kB:GFP fluorescence intensity in the islet region at 4 dpf. (E) Quantification of corrected area total cell NF-kB:GFP fluorescence in the islet region following DMSO or wedelolactone treatment, showing a reduction in NF-kB:GFP fluorescence. Unpaired two-tailed t-test with Welch's correction, ***P≤0.05. Mean±s.d.